ASTRAZENECA DL-,25 SP.ADR
ASTRAZENECA DL-,25 SP.ADR/ US0463531089 /
ZEGA
2024. 08. 28. 17:27:25
|
Vált.
+0,500
|
Forgalom (db) |
Vétel22:00:02 |
Eladás22:00:02 |
Piaci kapitalizáció |
Osztalékh. |
P/E Ráta |
78,000EUR
|
+0,65%
|
0 Forgalom: 0.000 |
-Vétel (db): - |
-Eladás (db): - |
242,64 mrd.EUR |
- |
- |
Cégbemutató
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Igazgatóság & Felügyelőbizottság
CEO |
Pascal Soriot |
Igazgatóság |
Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Menelas (Mene) Pangalos, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
Felügyelőbizottság |
Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg |